Xintela AB (publ) (FRA:1XT)

Market Cap	18.11M -39.6%
Revenue (ttm)	235.58K -36.3%
Net Income	-4.55M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0072
Previous Close	0.0072
Day's Range	0.0072 - 0.0072
52-Week Range	0.0072 - 0.0548
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Xintela AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 11
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1XT

Financial Performance

In 2025, Xintela AB's revenue was 2.28 million, a decrease of -45.86% compared to the previous year's 4.22 million. Losses were -48.56 million, 23.9% more than in 2024.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 27, 2026

Data Sources Report a data error